- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01701193
A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
A Randomized Double-Blind Controlled Proof-of-Concept Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The myriad medical and financial burdens of post-operative adhesions are well documented; however, treatment options are limited and controversial. Implantable physical barriers to prevent adhesions are commercially available, but most trials have failed to demonstrate compelling evidence to support widespread use. In recent years, advances have been made in our understanding of the cellular mechanisms underlying adhesiogenesis, raising the prospect of targeting these pathways to prevent post-surgical adhesions. However, to date, no drug has received regulatory approval for this purpose in any jurisdiction. Our study was designed to evaluate the efficacy and safety of a single intraoperative intraperitoneal dose of L-Alanyl-L-Glutamine (AG), an agent which has been shown to act upon key mediators in the adhesion formation pathway.
Methods: This was a randomized, double-blind, placebo-controlled study (DBRCT) of 47 women who underwent myomectomies by laparoscopy (N=37; AG-18 vs Placebo-19) or laparotomy (N=10; AG-5 vs Placebo-5) with a scheduled clinically necessary second-look laparoscopy (SLL) 6 - 8 weeks later. Digital recordings were obtained for all procedures. The primary endpoint was reduction in the incidence, severity and extent of post-operative adhesions, as analyzed by intention-to-treat (ITT) approach.
Three independent, blinded reviewers evaluated the operative video recordings to assess for presence of adhesions. Secondary endpoints assessed the safety and tolerability of AG. Post-hoc analysis assessed presence or absence of adhesions in the peritoneal cavity. Patients included those with previous history of surgery, endometriosis, and adhesiolysis was permitted at myomectomy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kharkiv, Ukraine
- 8Surgery and Endoscopy Department of Kharkiv Medical Academy of Postgraduate Education Kharkiv City Clinical Multi-field Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects are female
- Subjects are 18 years of age or older at the time of consent
- Subjects have a BMI between 17-40
- Subjects must have signed informed consent form
- Subjects have a preoperative diagnosis of uterine fibroids and plan to have a myomectomy completed surgically as part of their standard of care
- Subjects must have a physical examination and compliance assessment
Exclusion Criteria:
- Subjects whose BMI is outside the range of 17-40
- Subjects participating in another clinical trial with a drug or device
- Subjects who have participated in a clinical trial with a drug or device within 30 days prior to this study
- Subjects with suspected or diagnosed pregnancy
- Subjects with suspected intraabdominal infection
- Subjects who are immunocompromised
- Subjects diagnosed with cancer
- Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized cellulose)
- Subjects treated with adhesion prevention agents other than the Anti-Adhesion product (APP) (e.g. Intergel ® Adhesion Prevention Solution, Seprafilm ® Membrane)
- Subjects taking anti-epileptic medication
- Subjects who have been treated with Methotrexate or other chemotherapeutics agents
- Subjects with an American Fertility Society score of Stage D at the time of myomectomy as determined by the surgeon
- Positive viral serology screening results for hepatitis B surface antigen, antibodies to hepatitis C virus or human immunodeficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Physiological saline- Laparoscopic
Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
|
Placebo
|
Experimental: L-Alanyl/L-Glutamine- Laparoscopic
Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
|
Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection.
It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery.
The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
Other Names:
|
Placebo Comparator: Physiological saline- Laparotomy
Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
|
Placebo
|
Experimental: L-Alanyl/L-Glutamine- Laparotomy
Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
|
Sterile solution of L-Alanyl-L-Glutamine, 400mg/mL in water for injection.
It is dosed at 1g/kg of body weight and is instilled into the peritoneum at the time of surgery.
The active ingredient, glutamine, is a conditionally essential amino acid component of nutritional supplements.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants in Which Adhesions Were Prevented.
Time Frame: 6-8 weeks
|
The American Fertility Society (AFS) grading system for adhesions was used to assess incidence of adhesions.
Adhesion prevention was determined through grading of adhesions at the time of myomectomy (initial surgery) and at the time of second look surgery and compared.
|
6-8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events, Adverse Drug Reactions and Clinical Laboratory Abnormalities.
Time Frame: 8 weeks
|
Participants With Treatment-related Adverse Events as Assessed by Clinical Blood Work Abnormalities and Physical Examination.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Donna Chizen, MD, FRCSC, University of Saskatchewan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Ade002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pelvic Adhesions
-
Amsterdam UMC, location VUmcCompletedAdhesions Pelvic | Adhesion; Uterus | Adhesion; BladderNetherlands
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknownChronic Pain | Adhesions Abdominal | Surgery Induced Tissue Adhesions | Adhesions PelvicNetherlands
-
Shazia SaaqibKing Edward Medical University; Institute of Public Health, PakistanCompletedCesarean Section Complications | Bladder Injury | Adhesions PelvicPakistan
-
University of Missouri-ColumbiaCompletedLow Back Pain | Pelvic Pain | Adhesions | Scar TissueUnited States
-
First Affiliated Hospital, Sun Yat-Sen UniversityCompletedChronic Endometritis | Intrauterine Adhesions
-
Karnataka Institute of Medical SciencesCompletedTissue Adhesions | Nasal Synechiae | Adhesions of Nasal Cavity | Nasal AdhesionsIndia
-
University of SurreyEthicon Endo-SurgeryCompleted
-
University Hospital TuebingenCompleted
-
The University of Hong KongRecruitingSurgical AdhesionsHong Kong
Clinical Trials on Physiologic saline
-
University of MichiganSanofi Pasteur, a Sanofi CompanyCompleted
-
Laval UniversityCanadian Institutes of Health Research (CIHR); Centre de Recheche du Centre...WithdrawnAcute Viral Bronchiolitis.Canada
-
Altair Therapeutics, Inc.Completed
-
CSL BehringICON Clinical ResearchTerminatedAntibody-mediated RejectionKorea, Republic of, United States, New Zealand, Spain, Taiwan, Netherlands, Australia, France, Canada, Belgium, Czechia, Hungary, Sweden, Austria, Germany
-
Ferhat SayCompletedKnee Osteoarthritis | Cartilage DegenerationTurkey
-
Hospital Universitari de BellvitgeSpanish Clinical Research Network - SCReNUnknownIntraoperative BleedingSpain
-
Altair Therapeutics, Inc.Completed
-
Fundacion Clinica Valle del LiliTerminatedAbdominal InjuriesColombia
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)Completed
-
Carol Davila University of Medicine and PharmacyS.C. Sanador S.R.LActive, not recruitingEndothelial Dysfunction | Oxidative Stress | Renal Anemia | Iron ToxicityRomania